Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Blood. 2010 Mar 11;115(10):2095-104. doi: 10.1182/blood-2009-10-248716. Epub 2009 Dec 30.
Enabling engraftment of allogeneic T cell-depleted bone marrow (TDBM) under reduced-intensity conditioning represents a major challenge in bone marrow transplantation (BMT). Anti-third-party cytotoxic T lymphocytes (CTLs) were previously shown to be endowed with marked ability to delete host antidonor T cells in vitro, but were found to be less effective in vivo. This could result from diminished lymph node (LN) homing caused by the prolonged activation, which induces a CD44(+)CD62L(-) effector phenotype, and thereby prevents effective colocalization with, and neutralization of, alloreactive host T cells (HTCs). In the present study, LN homing, determined by imaging, was enhanced upon culture conditions that favor the acquisition of CD44(+)CD62L(+) central memory cell (Tcm) phenotype by anti-third-party CD8(+) cells. These Tcm-like cells displayed strong proliferation and prolonged persistence in BM transplant recipients. Importantly, adoptively transferred HTCs bearing a transgenic T-cell receptor (TCR) with antidonor specificity were efficiently deleted only by donor-type Tcms. All these attributes were found to be associated with improved efficacy in overcoming T cell-mediated rejection of TDBM, thereby enabling high survival rate and long-term donor chimerism, without causing graft-versus-host disease. In conclusion, anti-third-party Tcms, which home to recipient LNs and effectively delete antidonor T cells, could provide an effective and novel tool for overcoming rejection of BM allografts.
在低强度预处理条件下实现异基因 T 细胞耗竭骨髓(TDBM)的植入是骨髓移植(BMT)中的一个主要挑战。先前的研究表明,抗第三方细胞毒性 T 淋巴细胞(CTLs)具有显著的体外删除宿主抗供体 T 细胞的能力,但在体内效果较差。这可能是由于延长的激活导致淋巴结(LN)归巢减少所致,这种激活导致 CD44(+)CD62L(-)效应表型,从而阻止与同种反应性宿主 T 细胞(HTCs)的有效共定位和中和。在本研究中,通过成像确定 LN 归巢,通过有利于抗第三方 CD8(+)细胞获得 CD44(+)CD62L(+)中央记忆细胞(Tcm)表型的培养条件得到增强。这些 Tcm 样细胞在 BM 移植受者中表现出强烈的增殖和持久的持久性。重要的是,只有供体型 Tcms 才能有效地删除携带抗供体特异性 T 细胞受体(TCR)的同种异体 HTCs。所有这些特性都与提高克服 T 细胞介导的 TDBM 排斥反应的疗效有关,从而实现高存活率和长期供体嵌合,而不会引起移植物抗宿主病。总之,归巢到受者 LN 并有效删除抗供体 T 细胞的抗第三方 Tcms 可以为克服 BM 同种异体移植物排斥反应提供一种有效且新颖的工具。